CleanSpace Holdings Ltd (ASX: CSX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
CleanSpace Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
CleanSpace Holdings Ltd (ASX: CSX)
Latest News
Share Market News
The Cleanspace (ASX:CSX) share price is soaring 12% higher today. Here's why.
Share Market News
Here's how Adore Beauty (ASX:ABY) and these new IPOs have fared since listing
Frequently Asked Questions
-
No. Cleanspace has not yet paid out any dividends.
-
Cleanspace listed on 23 October 2020.
CSX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About CleanSpace Holdings Ltd
Cleanspace Holdings Ltd (ASX: CSX) designs, manufactures, and sells workplace respiratory protection equipment (RPE) for healthcare and industrial markets. Its products include Compare, CleanSpace HALO, CleanSpace ULTRA, masks, filters, and compatible products.
Its respirators are used in industries including mining, welding, stonemasonry, firefighting, construction, and wastewater. In the healthcare sector, they are used by hospitals, aged care facilities, air rescue, laboratories, first responders, and pharmaceuticals. Cleanspace has clients in more than 36 countries.
CSX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
01 Nov 2024 | $0.49 | $0.01 | 2.06% | 339 | $0.49 | $0.49 | $0.49 |
30 Oct 2024 | $0.49 | $-0.03 | -5.83% | 2,647 | $0.49 | $0.49 | $0.49 |
29 Oct 2024 | $0.52 | $0.03 | 6.12% | 8,835 | $0.51 | $0.52 | $0.49 |
28 Oct 2024 | $0.49 | $-0.01 | -2.02% | 242,909 | $0.50 | $0.53 | $0.49 |
25 Oct 2024 | $0.50 | $-0.02 | -3.92% | 7,579 | $0.50 | $0.50 | $0.50 |
24 Oct 2024 | $0.51 | $0.00 | 0.00% | 2,108 | $0.51 | $0.51 | $0.51 |
23 Oct 2024 | $0.51 | $0.03 | 6.19% | 6,074 | $0.50 | $0.51 | $0.50 |
22 Oct 2024 | $0.49 | $0.00 | 0.00% | 7,797 | $0.49 | $0.49 | $0.49 |
21 Oct 2024 | $0.49 | $-0.03 | -5.88% | 3,030 | $0.49 | $0.51 | $0.49 |
17 Oct 2024 | $0.51 | $-0.04 | -7.34% | 6,119 | $0.52 | $0.52 | $0.50 |
16 Oct 2024 | $0.55 | $0.05 | 10.00% | 26,552 | $0.51 | $0.55 | $0.51 |
15 Oct 2024 | $0.50 | $-0.02 | -3.85% | 17,778 | $0.51 | $0.52 | $0.47 |
14 Oct 2024 | $0.52 | $0.04 | 8.25% | 30,296 | $0.49 | $0.52 | $0.49 |
11 Oct 2024 | $0.49 | $-0.01 | -2.04% | 6,892 | $0.48 | $0.49 | $0.48 |
10 Oct 2024 | $0.49 | $-0.01 | -2.02% | 11 | $0.49 | $0.49 | $0.49 |
08 Oct 2024 | $0.50 | $0.02 | 4.17% | 237 | $0.48 | $0.50 | $0.48 |
07 Oct 2024 | $0.48 | $0.00 | 0.00% | 3,952 | $0.50 | $0.50 | $0.48 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
14 Oct 2024 | Graham McLean | Buy | 18,750 | $9,750 |
Conversion of securities. estimated value
|
14 Oct 2024 | Graham McLean | Exercise | 18,750 | $9,750 |
Conversion of securities. estimated value, 656,250 RSUs
|
18 Jul 2024 | Graham McLean | Exercise | 18,750 | $5,718 |
Conversion of securities. 675,000 Rights and rsu
|
18 Jul 2024 | Graham McLean | Buy | 18,750 | $5,718 |
Conversion of securities.
|
14 May 2024 | Dan Kao | Buy | 4,000 | $1,200 |
On-market trade.
|
13 May 2024 | Dan Kao | Buy | 6,446 | $1,953 |
On-market trade.
|
08 Apr 2024 | Graham McLean | Exercise | 18,750 | $6,000 |
Conversion of securities. 693,750 RSU and Rights
|
08 Apr 2024 | Graham McLean | Buy | 18,750 | $6,000 |
Conversion of securities.
|
24 Nov 2023 | Graham McLean | Issued | 37,500 | $12,375 |
Conversion of securities.
|
24 Nov 2023 | Graham McLean | Issued | 750,000 | $75,650 |
Issue of securities. 750,000 RSU AnD Rights
|
24 Nov 2023 | Graham McLean | Issued | 155,600 | $55,549 |
Issue of securities.
|
24 Nov 2023 | Graham McLean | Exercise | 37,500 | $12,375 |
Conversion of securities. 7,12,500 RSU & rights
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Bruce Rathie | Non-Executive DirectorNon-Executive Chairman | Oct 2021 |
Mr Rathie is an experienced Company Director having completed prior careers in law and investment banking. He practised as a partner in a legal firm and acted as Senior Corporate Counsel to Bell Resources Limited in the early to mid-1980s. Mr Rathie was Head of the Industrial Franchise Group at Salomon Smith Barney in the late 1990s and led Salomons roles in the Federal Government's privatisations of Qantas, Commonwealth Bank and Telstra. He has over 20 years of experience as a professional non-executive company director. In the medical device space, Mr Rathie was previously Chairman of Anteo Diagnostics Limited and a Director of Compumedics Limited and USCOM Limited.
|
Mr Dan Kao | Director-Operations & FounderExecutive Director | Apr 2011 |
Mr Kao, a former senior designer for ResMed Inc. (Australia), founded the business of CleanSpace in 2009. Mr Kao worked in the Industrial and healthcare setting for over 20 years, and has experience in manufacturing, supply chain optimisation, quality management systems and in securing patents for innovative technologies.
|
Ms Lisa Ray Hennessy | Non-Executive Director | Dec 2021 |
Ms Hennessy is experienced executive and company director with over 30 years of experience worldwide. Lisa has built a career in Australia including her role as an angel investor and has non-executive director experience across listed and private organisations. Ms Hennessy sits on the boards of Aikenhead Centre for Medical Discovery (ACMD), and the Harvard Club of Victoria. She was previously on the board of Walter and Eliza Hall Institute of Medical Research Commercialisation Committee, Planet Innovation, FirstStep Investments and Arts Centre Melbourne Foundation. Prior to this, Lisa held strategy and M&A roles in the US, including Director of Strategy and M&A for Del Monte Foods, Director of M&A at GE Capital, and was also a Consultant at Bain & Company.
|
Mr Graham McLean | Executive DirectorChief Executive Officer | Feb 2022 |
Mr McLean is senior executive, having worked with NYSE-listed Stryker for 16-years, and brings operational and healthcare experience. Stryker is a global company offering a range of products and services, including healthcare PPE, sold via distributors and direct sales. At Stryker, Mr McLean held positions, including President Japan, President Australia/New Zealand and President Asia Pacific, based in Singapore and Hong Kong. During this time, Mr McLean was responsible for transforming Asia Pacific, including restructuring their China distribution to accelerate growth of the business, resulting in Asia Pacific becoming a growing, multi-billion-dollar sales region. Mr McLean is a Non-Executive Director of Fisher & Paykel Healthcare Ltd, and a board member/Chair of Suicide Prevention Australia.
|
Mr Paul Cassano | Non-Executive Director | Sep 2023 |
Mr Cassano has over 30 years resources industry experience in senior executive and operations management roles with companies including BHP, Thiess and Downer where he was most recently CEO Mining, leading teams to business outcomes and embedding a positive culture. Mr Cassano brings technical and leadership experience and has global and multinational company experience.
|
Ms Elissa Hansen | Company Secretary | Nov 2020 |
-
|
Bree Greef | Chief Financial Officer |
-
|
|
Elissa Hansen | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
J P Morgan Nominees Australia Pty Limited | 10,579,980 | 13.67% |
Acme Co No 7 Pty Ltd <Cvc Emerging Comp Investee> | 9,257,535 | 11.96% |
Mutual Trust Pty Ltd | 3,788,936 | 4.90% |
Chatswood Wealth Management Pty Ltd | 3,227,400 | 4.17% |
Alex Birrell <Baf A/C> | 2,798,962 | 3.62% |
HSBC Custody Nominees (Australia) Limited | 2,791,149 | 3.61% |
Dan Kao | 2,530,000 | 3.27% |
Min Fang | 2,057,248 | 2.65% |
Acorn Capital Private Opportunities Fund L P | 1,670,391 | 2.16% |
Citicorp Nominees Pty Limited | 1,525,345 | 1.97% |
Mr Alfred Harry Hugh Myers <Lucy'S A/C> | 1,449,481 | 1.87% |
Miss Linda Ying Wang <Kao And Wang Family A/C> | 1,402,816 | 1.81% |
UBS Nominees Pty Ltd | 1,391,043 | 1.80% |
BNP Paribas Noms (Nz) Ltd | 1,205,929 | 1.55% |
Columbus Investment Services Ltd <Kelly Partners #2 A/C> | 1,191,542 | 1.54% |
Mr Ching Ming Liu | 994,842 | 1.29% |
Garrett Smythe Ltd | 885,321 | 1.14% |
Mr Joe Ching Wei Kao | 857,658 | 1.11% |
Jenny Hsu | 815,734 | 1.05% |
Rubino Group Pty Ltd <Rubino Group A/C> | 800,000 | 1.03% |